Zhongxin Jingwei, December 21 - Shanghai Model Biology announced on the evening of the 21st that the company and three senior executives received a warning letter from the Shanghai Securities Regulatory Bureau.
Screenshot of the announcement of Shanghai Model Biology.
The warning letter shows that after investigation, the following facts exist in Shanghai Model Organisms:
In July 2022, the company purchased 100% equity of Shanghai Zhongying Health Technology Co., Ltd. (hereinafter referred to as Zhongying Health). The main purpose of this acquisition is to obtain the industrial land and real estate facilities of Zhongyingjian, and this acquisition should be accounted for as an asset acquisition, but the company will account for this acquisition as a business combination not under the same control, resulting in inaccurate disclosure of the third quarter report of 2022 and the annual performance forecast of 2022. The details are as follows:
1) The disclosure of the third quarter report of 2022 is inaccurate.
On April 28, 2023, the company disclosed a correction announcement for the third quarter of 2022, and the total profit increased from 412 after the reduction of non-operating income300,000 yuan was adjusted to -373780,000 yuan, net profit by 778580,000 yuan was adjusted to -7510,000 yuan, the performance of the direction of profit and loss changed.
2) The disclosure of the 2022 annual results forecast is inaccurate.
On January 31, 2023, when the company disclosed the 2022 annual performance forecast, it was expected that the net profit attributable to the parent company would be 2 million to 3 million yuan. On April 28, 2023, the company disclosed its 2022 annual report, and the net profit attributable to the parent company in 2022 was -539960,000 yuan, the net profit attributable to the parent disclosed in the annual report and the performance forecast disclosed on January 31 showed a change in the direction of profit and loss.
The Shanghai Securities Regulatory Bureau decided to take the supervision and management measures of issuing a warning letter to Shanghai Model Organisms.
Fei Jian, as the chairman of the company, Wang Mingjun as the general manager of the company, and Qiang Yiwei, as the company's financial director at the time, failed to perform their duties diligently and were responsible for the company's above-mentioned behaviors.
Shanghai Model Biology said that this administrative supervision measure will not affect the company's normal operation and management activities.
According to public information, the main business of Shanghai Model Biology is the research and development, production and technical services of genetically modified model organisms. The company's main products and services include genetically modified animal model products and genetically modified animal model technical services.
In terms of performance, the operating income in the third quarter of 2023 was 87.21 million yuan, a year-on-year increase of 208%；The net profit loss attributable to the parent company was 11.71 million yuan. The growth rate of operating income slowed down in the third quarter, and Shanghai Model Biology said that it was mainly due to the increased financial pressure of downstream industrial customers affected by the investment and financing environment. The demand of scientific research customers is good, and the income of scientific research is growing rapidly.
In the secondary market, as of the 21st**, Shanghai Model Biology closed up 008% to 37$8. (Zhongxin Jingwei app).
For more exciting content, please pay attention to the official WeChat of JWVIEW***